BR112019008374A2 - inibidor seletivo de egfr mutante por inserção do éxon 20 - Google Patents

inibidor seletivo de egfr mutante por inserção do éxon 20

Info

Publication number
BR112019008374A2
BR112019008374A2 BR112019008374A BR112019008374A BR112019008374A2 BR 112019008374 A2 BR112019008374 A2 BR 112019008374A2 BR 112019008374 A BR112019008374 A BR 112019008374A BR 112019008374 A BR112019008374 A BR 112019008374A BR 112019008374 A2 BR112019008374 A2 BR 112019008374A2
Authority
BR
Brazil
Prior art keywords
egfr inhibitor
mutant egfr
selective exon
insert mutant
exon insert
Prior art date
Application number
BR112019008374A
Other languages
English (en)
Inventor
Miyadera Kazutaka
Hasako Shinichi
Aoyagi Yoshimi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of BR112019008374A2 publication Critical patent/BR112019008374A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

agente antitumoral compreendendo um composto selecionado do grupo consistindo nos compostos a a d descritos na descrição, ou um sal dos mesmos, para tratar um paciente com tumor maligno que expressa egfr tendo mutação por inserção do éxon 20.
BR112019008374A 2016-10-31 2017-10-13 inibidor seletivo de egfr mutante por inserção do éxon 20 BR112019008374A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016213072 2016-10-31
PCT/JP2017/037186 WO2018079310A1 (ja) 2016-10-31 2017-10-13 エクソン２０挿入変異型ｅｇｆｒ選択的阻害剤

Publications (1)

Publication Number Publication Date
BR112019008374A2 true BR112019008374A2 (pt) 2019-10-01

Family

ID=62024991

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019008374A BR112019008374A2 (pt) 2016-10-31 2017-10-13 inibidor seletivo de egfr mutante por inserção do éxon 20

Country Status (22)

Country Link
US (2) US11857513B2 (pt)
EP (1) EP3533449B1 (pt)
JP (1) JP6896755B2 (pt)
KR (1) KR102639585B1 (pt)
CN (1) CN110191711B (pt)
AU (1) AU2017350440B2 (pt)
BR (1) BR112019008374A2 (pt)
CA (1) CA3041015A1 (pt)
DK (1) DK3533449T3 (pt)
ES (1) ES2955832T3 (pt)
FI (1) FI3533449T3 (pt)
HU (1) HUE063712T2 (pt)
IL (1) IL266239B2 (pt)
JO (1) JOP20190073A1 (pt)
MX (1) MX2019004969A (pt)
PH (1) PH12019500957A1 (pt)
PL (1) PL3533449T3 (pt)
PT (1) PT3533449T (pt)
SG (1) SG11201903875QA (pt)
TW (1) TWI774699B (pt)
WO (1) WO2018079310A1 (pt)
ZA (1) ZA201902629B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
SG11202106986VA (en) * 2018-12-28 2021-07-29 Taiho Pharmaceutical Co Ltd L718 and/or l792 mutant treatment-resistant egfr inhibitor
JP6960064B2 (ja) 2019-02-15 2021-11-05 大鵬薬品工業株式会社 ７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−アミン誘導体
CN115181104A (zh) * 2019-09-29 2022-10-14 深圳市塔吉瑞生物医药有限公司 取代的稠合三环衍生物及其组合物及用途
CN113861195B (zh) * 2020-06-30 2022-11-18 上海和誉生物医药科技有限公司 一种多稠环egfr抑制剂及其制备方法和应用
WO2022007841A1 (zh) * 2020-07-09 2022-01-13 上海和誉生物医药科技有限公司 一种egfr抑制剂、其制备方法和在药学上的应用
WO2022055895A1 (en) * 2020-09-08 2022-03-17 Cullinan Pearl Corp. Treatment regimens for exon-20 insertion mutant egfr cancers
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
CN115785107A (zh) * 2022-12-15 2023-03-14 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW440562B (en) 1994-05-20 2001-06-16 Taiho Pharmaceutical Co Ltd Condensed-indan derivative and pharmaceutically acceptable salts thereof
AU2006227447A1 (en) 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-RAF kinase
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
WO2011004610A1 (ja) 2009-07-10 2011-01-13 大鵬薬品工業株式会社 アザ二環式化合物又はその塩
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
MX2013007938A (es) 2011-01-07 2013-11-01 Taiho Pharmaceutical Co Ltd Compuesto biciclico novedoso o sal del mismo.
WO2013047813A1 (ja) 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
TW201336847A (zh) 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
ES2580530T3 (es) 2012-02-23 2016-08-24 Taiho Pharmaceutical Co., Ltd. Compuesto con anillo fusionado de quinolilpirrolopirimidilo o sal del mismo
KR20150119401A (ko) 2013-02-22 2015-10-23 다이호야쿠힌고교 가부시키가이샤 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물
HUE034807T2 (en) 2013-08-22 2018-02-28 Taiho Pharmaceutical Co Ltd New quinoline-substituted compound
WO2015175632A1 (en) 2014-05-13 2015-11-19 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
BR112016029662B1 (pt) 2014-06-19 2023-10-24 Takeda Pharmaceutical Company Limited COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO
JP6583614B2 (ja) 2015-05-11 2019-10-02 大同特殊鋼株式会社 アーク炉の電極折損防止装置
JOP20200044A1 (ar) 2017-09-01 2020-02-26 Taiho Pharmaceutical Co Ltd مثبط انتقائي egfr طافر exon 18 و/أو exon 21

Also Published As

Publication number Publication date
JPWO2018079310A1 (ja) 2019-09-12
CA3041015A1 (en) 2018-05-03
US11857513B2 (en) 2024-01-02
CN110191711B (zh) 2022-09-23
IL266239A (en) 2019-06-30
IL266239B2 (en) 2023-10-01
ZA201902629B (en) 2023-12-20
EP3533449B1 (en) 2023-07-12
JP6896755B2 (ja) 2021-06-30
US20190262345A1 (en) 2019-08-29
ES2955832T3 (es) 2023-12-07
RU2019116780A (ru) 2020-11-30
PL3533449T3 (pl) 2023-11-20
PT3533449T (pt) 2023-09-21
CN110191711A (zh) 2019-08-30
HUE063712T2 (hu) 2024-01-28
IL266239B1 (en) 2023-06-01
FI3533449T3 (fi) 2023-09-15
JOP20190073A1 (ar) 2019-04-07
AU2017350440B2 (en) 2023-01-12
KR102639585B1 (ko) 2024-02-23
MX2019004969A (es) 2019-09-18
RU2019116780A3 (pt) 2020-12-28
EP3533449A4 (en) 2020-06-17
WO2018079310A1 (ja) 2018-05-03
TW201821079A (zh) 2018-06-16
SG11201903875QA (en) 2019-05-30
PH12019500957A1 (en) 2019-08-05
AU2017350440A1 (en) 2019-05-16
KR20190080901A (ko) 2019-07-08
EP3533449A1 (en) 2019-09-04
DK3533449T3 (da) 2023-10-09
US20240148734A1 (en) 2024-05-09
TWI774699B (zh) 2022-08-21

Similar Documents

Publication Publication Date Title
BR112019008374A2 (pt) inibidor seletivo de egfr mutante por inserção do éxon 20
BR112018004620A2 (pt) moduladores da expressão de kras
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
BR112016027048A8 (pt) uso de um composto de fórmula i no tratamento de câncer cerebral e glioblastoma multiforme mgmt positivo
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
BR112017028194A2 (pt) moduladores de diaciglicerol aciltransferase 2 (dgat2)
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
AU2016304856A8 (en) Mechanism of resistance to BET bromodomain inhibitors
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
PH12020552060A1 (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
BR112016028641A2 (pt) ?método para tratar câncer?
DOP2021000044A (es) Moduladores de la expresión de pnpla3
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
MX2018014577A (es) Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b.
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
BR112017027277A2 (pt) ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
PE20210109A1 (es) Moduladores de la expresion de irf4
ECSP20082339A (es) Moduladores de la expresión de apol1
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112016008901A2 (pt) Compostos para uso na prevenção e tratamento de doenças neurodegenerativas e da dor.
CO2020003134A2 (es) Moduladores de la expresión de enac
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
UY38472A (es) Moduladores de la expresión de foxp3

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]